ALVOTECH news, videos and press releases
For more news please use our advanced search feature.
ALVOTECH - More news...
ALVOTECH - More news...
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
- Alvotech Announces Closing of Private Debt Financing
- Alvotech Announces Closing of Private Debt Financing
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech Issues New Shares to Holders of Convertible Bonds
- Alvotech Issues New Shares to Holders of Convertible Bonds
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
- Alvotech Receives Conversion Notices for Majority of Convertible Bonds
- Alvotech Receives Conversion Notices for Majority of Convertible Bonds
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
- Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
- Alvotech and STADA add to strategic alliance through denosumab partnership
- Alvotech Announces Strategic Refinancing Agreement
- Alvotech Announces Strategic Refinancing Agreement